US Senate Approves Bipartisan Marijuana Research Bill

Nov.18.2022
US Senate Approves Bipartisan Marijuana Research Bill
US Senate approves bipartisan marijuana research bill expanding medical marijuana and THC research opportunities.

An independent marijuana reform legislation has been sent to the desk of the President of the United States for the first time. The "Medical Marijuana and Cannabinoid Research Expansion Act" is just one step away from historic legislation.


Just a few weeks after President Joe Biden announced a large-scale marijuana pardon and instructed a review of the drug's scheduling status, the US Senate on Wednesday approved a bipartisan marijuana research bill passed by the House of Representatives.


Senate Majority Leader Chuck Schumer has stated that he will continue to hold "productive conversations" regarding broader marijuana reform. According to Marijuana Moments, he hopes to pass these reforms before the current congressional session comes to a close.


Before the vote, Schumer stated that the bill "will eliminate red tape that impedes marijuana research and open the doors for innovative new therapies derived from marijuana." "If you are one of the millions of Americans suffering from Parkinson's, epilepsy, post-traumatic stress disorder, or any other illness, marijuana may offer promising new options for treatment.


We need to conduct research first," he said. "Unfortunately, the federal government is severely lagging behind in this area. This bill will help address this issue.


At a recent meeting, each chamber presented and advanced a number of marijuana measures. However, reform has stalled before reaching the president.


The bill was submitted in July and quickly passed in the House of Representatives, before being reviewed by the Senate, which approved the legislation unanimously.


Statement:


This article is a compilation of information obtained from third-party sources and is intended solely for industry professionals for exchange and learning purposes.


This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The translation of this article is only intended for industry research and communication purposes.


Due to limitations in the translation skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS aligns with the Chinese government's stance on all domestic, Hong Kong, Macau, Taiwan, and foreign-related issues and statements.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japanese Tobacco (JT) reports Q1 2026 revenue of 924 billion yen, a 15.2% increase; operating profit rises 24.7%.
May.08 by 2FIRSTS.ai
Revised Tobacco Business Act to Take Effect in South Korea, Banning Online Sales of Liquid Vapes
Revised Tobacco Business Act to Take Effect in South Korea, Banning Online Sales of Liquid Vapes
South Korea’s Ministry of Health and Welfare will implement a partial revision of the Tobacco Business Act on April 24. The scope will expand from products made with “tobacco leaves” to all products manufactured with natural or synthetic nicotine. Synthetic nicotine liquid e-cigarettes, which had previously been treated as industrial products and were freely sold and advertised online, will from April 24 be subject to the same regulations as ordinary tobacco products.
Apr.23 by 2FIRSTS.ai
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International announced on April 20 that IQOS has partnered with French acoustic engineering company Devialet to launch “Soundsorial Design” at Milan Design Week 2026. The collaboration includes an immersive exhibition and a limited-edition product set named “Soundsorial.” The exhibition will run from April 20 to April 27 at Opificio 31 in Milan.
Apr.22 by 2FIRSTS.ai
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
Turkey’s New Tobacco Bill Draft Would Cover E-Cigarettes and Heated Tobacco Products
Turkey’s New Tobacco Bill Draft Would Cover E-Cigarettes and Heated Tobacco Products
A Turkey’s draft would impose major limits on the use of tobacco products in public buildings, educational and healthcare institutions, children’s areas, and outdoor events, while setting a 2040 target for a complete ban on the production, sale, and consumption of tobacco products. The draft also broadens the definition of tobacco products to include e-cigarettes, heated tobacco products, and all nicotine-containing systems.
Apr.13 by 2FIRSTS.ai
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai